<head>
<title>Core Laboratories N.V. Third Amendment to the Third Amended and Restated
Credit Agreement</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report (Date of earliest event reported):<b>
      November 7, 2006 (November 6, 2006)</b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of registrant as specified in its charter)</p>
<p ALIGN="CENTER"><b>001-14273<br>
</b>(Commission File Number)</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<B><P>Item 1.01 Entry into Material Definitive Agreement</P>
</B><P>On November 6, 2006, Core Laboratories N.V. and certain of its subsidiaries, amended its Third Amended and Restated Credit Agreement (henceforth referred to as the "Amended Credit Agreement") with various financial institutions which are or may become parties to the Amended Credit Agreement (collectively, the "Lenders"), Bank of America, N.A. as administrative agent for the Lenders and as a letter of credit issuing bank. </P>
<P>The Amended Credit Agreement primarily includes the following changes: </P>

<div align="center">
  <center>
  <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse" bordercolor="#111111" width="85%">
    <tr>
      <td width="3%" align="center"><font size="2">-</font></td>
      <td width="97%"><font SIZE="2">
      Incorporates the Exchangeable Senior Notes issued by the Company on November 6, 2006 into various sections of the Amended Credit Agreement,
</font>
      </td>
    </tr>
    <tr>
      <td width="3%" align="center">&nbsp;</td>
      <td width="97%">&nbsp;</td>
    </tr>
    <tr>
      <td width="3%" align="center"><font size="2">-</font></td>
      <td width="97%"><font SIZE="2">
      Reduces the aggregate borrowing commitment under the existing credit facility from $125 million to $100 million,</font></td>
    </tr>
    <tr>
      <td width="3%" align="center">&nbsp;</td>
      <td width="97%">&nbsp;</td>
    </tr>
    <tr>
      <td width="3%" align="center"><font size="2">-</font></td>
      <td width="97%"><font SIZE="2">
      Improves the Leverage Ratio covenant (consolidated net indebtedness to consolidated EBITDA) from a ratio of 2.25 to 1.0 to the following; (a) 3.00 to 1.00 during the period from the Third Amendment Effective Date through the fiscal quarter ending March 31, 2008; (b) 2.75 to 1.00 during the period from the fiscal quarter beginning on April 1, 2008 through the fiscal quarter ending September 30, 2009; and (c) 2.50 to 1.00 during the period from the fiscal quarter beginning on October 1, 2009 through the Facility Termination Date,</font></td>
    </tr>
    <tr>
      <td width="3%" align="center">&nbsp;</td>
      <td width="97%">&nbsp;</td>
    </tr>
    <tr>
      <td width="3%" align="center"><font size="2">-</font></td>
      <td width="97%"><font SIZE="2">
      Improves the Coverage Ratio covenant (consolidated EBITDA to consolidated interest expense) to be not less than 3.0 to 1.0 from a previous ratio of 3.5 to 1.0 and
</font>
      </td>
    </tr>
    <tr>
      <td width="3%" align="center">&nbsp;</td>
      <td width="97%">&nbsp;</td>
    </tr>
    <tr>
      <td width="3%" align="center"><font size="2">-</font></td>
      <td width="97%"><font SIZE="2">
      Provides for lower borrowing costs as defined in the Amended Credit Agreement.&nbsp;
</font>
      </td>
    </tr>
  </table>
  </center>
</div>
<P ALIGN="JUSTIFY">In addition, the Amended Credit Agreement provides an option to increase the commitment under the credit facility to $150 million, if certain conditions are met. In July 2006, Core Laboratories N.V. had amended its Amended Credit Agreement to remove the Minimum Net Worth debt covenant ratio and also modify the Leverage Ratio
covenant&nbsp; (consolidated net indebtedness to consolidated EBITDA)  to 2.25 to 1.0 (previously 2.5 to 1.0).</P>
<P>The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Amended Credit Agreement, which is filed as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K and is incorporated herein by reference. </P>
<p>&nbsp;</p>
<b>
<p>Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits</p>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    <p style="TEXT-ALIGN: right" align="right"><font SIZE="2">(c)</font></td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" width="1%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 91%; PADDING-TOP: 0in" width="91%">
    <i><font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
</b>
<p>10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement</p>
<p>10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement</p>
<p>&nbsp;</p>
<b>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="TOP" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP"><font SIZE="2">
      <p>Dated: November 7, 2006</font></td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
<b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE" style="border-bottom-style: solid; border-bottom-width: 1"><b><font SIZE="2">
      <p>EXHIBIT NO.</font></b></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE" style="border-bottom-style: solid; border-bottom-width: 1"><b><font SIZE="2">
      <p>ITEM</font></b></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE" style="border-top-style: solid; border-top-width: 1">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE" style="border-top-style: solid; border-top-width: 1">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP"><font SIZE="2">
      <p>10.1</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP"><font SIZE="2">
      <p>Second Amendment to the Third Amended and Restated Credit Agreement</font></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP"><font size="2">10.2</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP"><font size="2">Third Amendment to the Third
    Amended and Restated Credit Agreement</font></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">&nbsp;</td>
  </tr>
</table>
</div>
</center>
<p ALIGN="left">&nbsp;</p>

</font>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_amendedrevolver.htm", "description": "8-K", "secsgml_size_bytes": 16242}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "061192374"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. Third Amendment to the Third Amended and Restated
Credit Agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
November 7, 2006 (November 6, 2006)
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 1.01 Entry into Material Definitive Agreement
On November 6, 2006, Core Laboratories N.V. and certain of its subsidiaries, amended its Third Amended and Restated Credit Agreement (henceforth referred to as the "Amended Credit Agreement") with various financial institutions which are or may become parties to the Amended Credit Agreement (collectively, the "Lenders"), Bank of America, N.A. as administrative agent for the Lenders and as a letter of credit issuing bank.
The Amended Credit Agreement primarily includes the following changes:
-
Incorporates the Exchangeable Senior Notes issued by the Company on November 6, 2006 into various sections of the Amended Credit Agreement,
-
Reduces the aggregate borrowing commitment under the existing credit facility from $125 million to $100 million,
-
Improves the Leverage Ratio covenant (consolidated net indebtedness to consolidated EBITDA) from a ratio of 2.25 to 1.0 to the following; (a) 3.00 to 1.00 during the period from the Third Amendment Effective Date through the fiscal quarter ending March 31, 2008; (b) 2.75 to 1.00 during the period from the fiscal quarter beginning on April 1, 2008 through the fiscal quarter ending September 30, 2009; and (c) 2.50 to 1.00 during the period from the fiscal quarter beginning on October 1, 2009 through the Facility Termination Date,
-
Improves the Coverage Ratio covenant (consolidated EBITDA to consolidated interest expense) to be not less than 3.0 to 1.0 from a previous ratio of 3.5 to 1.0 and
-
Provides for lower borrowing costs as defined in the Amended Credit Agreement.
In addition, the Amended Credit Agreement provides an option to increase the commitment under the credit facility to $150 million, if certain conditions are met. In July 2006, Core Laboratories N.V. had amended its Amended Credit Agreement to remove the Minimum Net Worth debt covenant ratio and also modify the Leverage Ratio
covenant  (consolidated net indebtedness to consolidated EBITDA)  to 2.25 to 1.0 (previously 2.5 to 1.0).
The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Amended Credit Agreement, which is filed as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits
(c)
Exhibits
10.1        Second Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement
10.2         Third Amendment to the Third Amended and Restated
First Amendment to the Third Amended and Restated
Credit Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: November 7, 2006
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
10.1
Second Amendment to the Third Amended and Restated Credit Agreement
10.2
Third Amendment to the Third
    Amended and Restated Credit Agreement